Sugammadex Reduces Antiemetic Effect of Dexamethasone

ConditionPONV
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAugusta University

About this trial

Sugammadex is a medication used for reversal of muscle relaxation during procedures under general anesthesia. It works by encapsulating muscle relaxant molecules with a steroid ring in its structure. On the other hand, postoporative nause and vomiting (PONV) is an adverse outcome during anesthesia. PONV can be prevented with pharmacologic agents such as ondansetron and dexamethasone. Dexamethasone is a steroidal agent that can interact with sugammadex. In theory, this interaction could lead to reduced effectiveness of sugammadex. In fact, several studies have explored this interaction. However, the effect of sugammadex on the antiemetic effect of dexamethasone has not been evaluated. This study intends to evaluate this interaction.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Older than 18 years old

Elective surgery

ASA 1, 2, 3

At least one risk factor for PONV

Disqualifiers

Pregnancy

Receiving antiemetics prior to arrival to preoperative holding area

Receiving opioids prior to arrival to preoperative holding area

Admission to ICU

Trial population

Adult surgical patients scheduled for elective surgery

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

100 Participants
are grouped into 2 trial groups
Group A: Dexamethasone
Group B: Dexamethasone + sugammadex

Trial outcomes

Primary outcomes

1

Rate of PONV

Number of events of PONV during 2 hours after admission to PACU

Time frame
2 hours after admission to PACU

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: